Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christina Lindahl
Observed names:
C Lindahl,
C. Lindahl,
Christina Lindahl Md,
Lindahl, C.
Institution:
Oslo University Hospital
Observed institutions:
Oslo University Hospital,
Pfizer (Sweden)
OpenAlex ID:
A5032600522
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction The IDEAL Study: A Randomized Controlled Trial
2005
·
Terje R. Pedersen
, Ole Faergeman
, et al.
·
JAMA
·
1,675
High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk
2008
·
Wim A. van der Steeg
, Ingar Holme
, et al.
·
Journal of the American College of Cardiology
·
411
PDF
Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
2009
·
Ole Faergeman
, Ingar Holme
, et al.
·
The American Journal of Cardiology
·
168
Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy
2009
·
Matti J. Tikkanen
, Michael Szarek
, et al.
·
Journal of the American College of Cardiology
·
67
Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)
2009
·
Matti J. Tikkanen
, Ingar Holme
, et al.
·
The American Journal of Cardiology
·
65
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
2004
·
Terje R. Pedersen
, Ole Faergeman
, et al.
·
The American Journal of Cardiology
·
57
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)
2008
·
Ingar Holme
, Nilo B. Cater
, et al.
·
Annals of Medicine
·
56
PDF
Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)
2010
·
Terje R. Pedersen
, Nilo B. Cater
, et al.
·
The American Journal of Cardiology
·
43
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
2010
·
I. Holme
, R. Fayyad
, et al.
·
Journal of Internal Medicine
·
28
Comparative Effect of Atorvastatin (80 mg) Versus Simvastatin (20 to 40 mg) in Preventing Hospitalizations for Heart Failure in Patients With Previous Myocardial Infarction
2009
·
Timo E. Strandberg
, Ingar Holme
, et al.
·
The American Journal of Cardiology
·
27
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study
2009
·
Ingar Holme
, Michael Szarek
, et al.
·
European Journal of Cardiovascular Prevention & Rehabilitation
·
22
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease
2009
·
Ingar Holme
, Timo E. Strandberg
, et al.
·
Atherosclerosis
·
15
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
2011
·
Anders G Olsson
, Christina Lindahl
, et al.
·
European Journal of Cardiovascular Prevention & Rehabilitation
·
13
Prognostic Model of Residual Risk for Major Cardiovascular Events in Statin-treated Coronary Patients: a Combined Analysis of the Ideal and Tnt Trials
2012
·
Ingar Holme
, Ole Faergeman
, et al.
·
Journal of the American College of Cardiology
·
2
PDF
Abstract 18079: Among CHD Patients in the IDEAL Study, Those with Elevated Levels of Alanine Aminotransferase at Baseline Had a Lower Rate of Major Coronary Events
2011
·
Matti J Tikkanen
, Rana Fayyad
, et al.
·
Circulation
·
1
Among CHD patients in the ideal study, those with elevated levels of alanine aminotransferase at baseline had a lower rate of major coronary events
2011
·
Tikkanen, M.J.
, Fayyad, R.
, et al.
CORONARY PATIENTS REACHING LDL-CHOLESTEROL < 2.0 mmol/L HAVE THE LOWEST RISK OF CARDIOVASCULAR EVENTS DURING STATIN TREATMENT: THE IDEAL STUDY
2010
·
A. Olsson
, C. Lindahl
, et al.
·
Atherosclerosis Supplements
Abstract: P824 CAN LIPID/APOLIPOPROTEIN FACTORS ACCOUNT FOR RESIDUAL RISK IN PATIENTS ATTAINING CURRENT LDL-C TARGETS?
2009
·
A Olsson
, C Lindahl
, et al.
·
Atherosclerosis Supplements
Effect of Differential Treatment Adherence in Recent Mi Patients in the Ideal Trial
2008
·
O. Faergeman
, I. Holme
, et al.
·
Atherosclerosis Supplements
Statins and Risk of Cardiovascular Events in Patients With Coronary Revascularization (cr) in the Ideal Trial
2008
·
T. Pedersen
, N. Cater
, et al.
·
Atherosclerosis Supplements
Importance of Triglycerides in Patients at Ldl-c Goal: Analysis of Incremental Decrease in Endponts Through Aggressive Lipid Lowering (ideal) Trial
2008
·
I. Holme
, N. Cater
, et al.
·
Atherosclerosis Supplements
Ldl Cholesterol Goal Attainments in the Ideal Study
2008
·
A.G. Olsson
, C. Lindahl
, et al.
·
Atherosclerosis Supplements
Intensive Atorvastatin Therapy Reduces Risk of Cardiovascular Events Beyond the First Event in Patients With Multiple Events
2008
·
M.J. Tikkanen
, N.B. Cater
, et al.
·
Atherosclerosis Supplements
Abstract 2455: Intensive Statin Therapy Reduces Risk of Cardiovascular Disease Beyond Occurrence of the First Event: Analysis of the Incremental Decrease in Endpoints through Aggressive Lipid Lowering Trial
2007
·
Matti J. Tikkanen
, Michael Szarek
, et al.
·
Circulation
Risk Reduction With Intensive Versus Standard Statin Therapy in Acute Coronary Syndrome: Ideal Trial
2007
·
T.R. Pedersen
, N.B. Cater
, et al.
·
Atherosclerosis Supplements
Show more works
View as search
Works count:
30
Citation count:
2,650
H-index:
13
I10-index:
13
Year
Topic
Type